Company aims to enhance drug discovery by observing the molecular changes that occur as people transition from health to disease over decades.
Longevity biotech BioAge Labs has announced that it will harness molecular data from the HUNT Biobank in Norway to expand the capabilities of its drug discovery platform. By analyzing biological samples gathered from more than 6,000 participants in the HUNT study, one of Europe’s largest and most extensively characterized population health cohorts, the company aims to generate millions of molecular readouts that will deepen its understanding of the biological mechanisms that support resilience and influence the development of aging-related diseases.